Drug Treatment of the Overweight Patient

Bray, George A.; Ryan, Donna H.

doi:10.1053/j.gastro.2007.03.053

Cited by 115Pharmacology and Obesity TreatmentBariatric Surgery and OutcomesObesity, Physical Activity, Diet

Drug Treatment of the Overweight Patient

Bray, George A., Ryan, Donna H.·2007·Gastroenterology

DOI 10.1053/j.gastro.2007.03.053

Open this paper in CoChat — free account

Abstract

Three medications with approval for long-term use in the treatment of obesity are currently available in the United States. Sibutramine (U.S. Food and Drug Administration [FDA] approved in 1997), orlistat (FDA approved in 1999), and rimonabant (available in Europe and given FDA approvable status in 2006 and expected to be marketed in 2007) represent modern approaches to medications used adjunctively for weight management. As demonstrated in large clinical trials of 2 to 4 years' duration, these medications significantly increase weight loss compared with placebo; weight loss with these drugs reaches a nadir between 20 and 28 weeks; weight loss, averaged 8%-10%, with the placebo contributing 4%-6% of that. Weight maintenance is demonstrated as long as adherence to medication continues. All medications have side effects that need to be considered. For sibutramine, there is a rise in blood pressure and heart rate that may require discontinuation of the drug in a small percent of patients. For orlistat, steatorrhea produces the principal gastrointestinal side effects. Rimonabant appears to have a favorable safety and tolerability profile. Nausea and gastrointestinal symptoms are the chief tolerability issue, but they are usually self-limited. In addition there are several drugs and drug combinations in phase 2 or phase 2 trials that will be reported on in the coming years.

Integrity signals

Registry

Crossref · 10.1053/j.gastro.2007.03.053

Cites

89 of 89 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Phentermine has the potential to raise BP and heart rate.
“Given the increased release of norepinephrine promoted by phentermine, it has the potential to raise BP and heart rate.194,195”
From Obesity‐Related Hypertension: Pathogenesis, Cardiovascular Risk, and Treatment: A Position Paper of The Obesity Society and the American Society of Hypertension (2013) · cites this paper as [195]

Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944 · see citing works
Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011 · see citing works
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011 · see citing works
Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: The evidence report
(1998) · PsycEXTRA Dataset · doi:10.1037/e565682010-001 · Cited by 9,452 · see citing works
Public Health Service
Bowman, P. W. (1963) · AIBS Bulletin · doi:10.2307/1292957 · Cited by 3,644 · see citing works
XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study
Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004) · Diabetes Care · doi:10.2337/diacare.27.1.155 · Cited by 1,915 · see citing works
Inhibition of Food Intake in Obese Subjects by Peptide YY 3–36
Batterham, R. L., Cohen, M. A., Ellis, S. M., Le Roux, C. W., Withers, D. J., Frost, G. S., Ghatei, M. A., & Bloom, S. R. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030204 · Cited by 1,604 · see citing works
Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes
DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559 · see citing works
Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study
Gaal, L. F. V., Rissanen, A., Scheen, A. J., Ziegler, O., & Rössner, S. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66374-x · Cited by 1,500 · see citing works
Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia
Després, J.-P., Golay, A., & Sjöström, L. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044537 · Cited by 1,392 · see citing works
Effects of exenatide (Exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes
Buse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346 · see citing works
Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients.
Sjöström, L., Rissanen, A., Andersen, T., Boldrin, M., Golay, A., Koppeschaar, H. P., & Krempf, M. (1998) · The Lancet · doi:10.1016/s0140-6736(97)11509-4 · Cited by 1,237 · see citing works
Effect of Rimonabant, a Cannabinoid-1 Receptor Blocker, on Weight and Cardiometabolic Risk Factors in Overweight or Obese Patients
Pi-Sunyer, X., Aronne, L. J., Heshmati, H. M., Devin, J., Rosenstock, J., & for the RIO-North America Study Group (2006) · JAMA · doi:10.1001/jama.295.7.761 · Cited by 1,209 · see citing works
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea
Kendall, D. M., Riddle, M. C., Rosenstock, J., Zhuang, D., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1083 · Cited by 1,177 · see citing works
Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement
Avenell, A., Broom, J., Brown, T., Poobalan, A., Aucott, L., Stearns, S., Smith, W., Jung, R., Campbell, M., & Grant, A. (2004) · Health Technology Assessment · doi:10.3310/hta8210 · Cited by 1,041 · see citing works
Weight Control and Risk Factor Reduction in Obese Subjects Treated for 2 Years With Orlistat: A Randomized Controlled Trial
Davidson, M. H., Hauptman, J., DiGirolamo, M., Foreyt, J. P., Halsted, C. H., Heber, D., Heimburger, D. C., Lucas, C. P., Robbins, D. C., Chung, J., et al. (1999) · JAMA · doi:10.1001/jama.281.3.235 · Cited by 947 · see citing works
The Emerging Role of the Endocannabinoid System in Endocrine Regulation and Energy Balance
Pagotto, U., Marsicano, G., Cota, D., Lutz, B., & Pasquali, R. (2005) · Endocrine Reviews · doi:10.1210/er.2005-0009 · Cited by 856 · see citing works
Effect of sibutramine on weight maintenance after weight loss: a randomised trial
James, W. P. T., Astrup, A., Finer, N., Hilsted, J., Kopelman, P., Rössner, S., Saris, W. H. M., & Gaal, L. F. V. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03491-7 · Cited by 817 · see citing works
Exenatide versus Insulin Glargine in Patients with Suboptimally Controlled Type 2 Diabetes: A Randomized Trial
Heine, R. J., Van Gaal, L. F., Johns, D., Mihm, M. J., Widel, M. H., Brodows, R. G., & for the GWAA Study Group* (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-143-8-200510180-00006 · Cited by 795 · see citing works
Randomized Trial of Lifestyle Modification and Pharmacotherapy for Obesity
Wadden, T. A., Berkowitz, R. I., Womble, L. G., Sarwer, D. B., Phelan, S., Cato, R. K., Hesson, L. A., Osei, S. Y., Kaplan, R., & Stunkard, A. J. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050156 · Cited by 794 · see citing works
Meta-Analysis: Pharmacologic Treatment of Obesity
Li, Z., Maglione, M., Tu, W., Mojica, W., Arterburn, D., Shugarman, L. R., Hilton, L., Suttorp, M., Solomon, V., Shekelle, P. G., et al. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-7-200504050-00012 · Cited by 774 · see citing works
H1-Receptor Antagonists
Estelle, F., & Simons, R. (1994) · Drug Safety · doi:10.2165/00002018-199410050-00002 · Cited by 751 · see citing works
Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study
Hollander, P. A., Elbein, S. C., Hirsch, I. B., Kelley, D., McGill, J., Taylor, T., Weiss, S. R., Crockett, S. E., Kaplan, R. A., Comstock, J., et al. (1998) · Diabetes Care · doi:10.2337/diacare.21.8.1288 · Cited by 654 · see citing works
Effect of Orlistat on Weight and Body Composition in Obese Adolescents: A Randomized Controlled Trial
Chanoine, J.-P., Hampl, S., Jensen, C., Boldrin, M., & Hauptman, J. (2005) · JAMA · doi:10.1001/jama.293.23.2873 · Cited by 624 · see citing works
The Cannabinoid CB1 Receptor Antagonist SR141716 Increases Acrp30 mRNA Expression in Adipose Tissue of Obese fa/fa Rats and in Cultured Adipocyte Cells
Bensaïd, M., Gary‐Bobo, M., Esclangon, A., Maffrand, J., Fur, G. L., Oury-Donat, F., & Soubrié, P. (2003) · Molecular Pharmacology · doi:10.1124/mol.63.4.908 · Cited by 593 · see citing works
Obesity
Yanovski, S. Z., & Yanovski, J. A. (2002) · New England Journal of Medicine · doi:10.1056/nejmra012586 · Cited by 544 · see citing works
Weight Loss, Weight Maintenance, and Improved Cardiovascular Risk Factors after 2 Years Treatment with Orlistat for Obesity
Rössner, S., Sjöström, L., Noack, R., Meinders, A. E., Noseda, G., & Study, O. B. O. T. E. O. O. (2000) · Obesity Research · doi:10.1038/oby.2000.8 · Cited by 476 · see citing works
Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers
Edwards, C. M. B., Stanley, S. A., Davis, R. P., Brynes, A. E., Frost, G. S., Seal, L., Ghatei, M. A., & Bloom, S. R. (2001) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2001.281.1.e155 · Cited by 464 · see citing works
Subcutaneous Oxyntomodulin Reduces Body Weight in Overweight and Obese Subjects
Wynne, K., Park, A. J., Small, C. J., Patterson, M., Ellis, S. M., Murphy, K. G., Wren, A. M., Frost, G. S., Meeran, K., Ghatei, M. A., et al. (2005) · Diabetes · doi:10.2337/diabetes.54.8.2390 · Cited by 435 · see citing works
Behavior Therapy and Sibutramine for the Treatment of Adolescent Obesity: A Randomized Controlled Trial
Berkowitz, R. I., Wadden, T. A., Tershakovec, A. M., & Cronquist, J. L. (2003) · JAMA · doi:10.1001/jama.289.14.1805 · Cited by 389 · see citing works
Long-term pharmacotherapy for obesity and overweight
Padwal, R. S., Rucker, D., Li, S. K., Curioni, C., & Lau, D. C. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004094.pub2 · Cited by 384 · see citing works
Sibutramine Produces Dose‐Related Weight Loss
Bray, G. A., Blackburn, G. L., Ferguson, J. M., Greenway, F. L., Jain, A. K., Mendel, C. M., Mendels, J., Ryan, D. H., Schwartz, S. L., Scheinbaum, M. L., et al. (1999) · Obesity Research · doi:10.1002/j.1550-8528.1999.tb00701.x · Cited by 383 · see citing works
Self-citation
Entry of exendin-4 into brain is rapid but may be limited at high doses
Kastin, A., & Akerstrom, V. (2003) · International Journal of Obesity · doi:10.1038/sj.ijo.0802206 · Cited by 362 · see citing works
Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults
Heymsfield, S. B., Segal, K. R., Hauptman, J., Lucas, C. P., Boldrin, M. N., Rissanen, A., Wilding, J. P. H., & Sjöström, L. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.9.1321 · Cited by 358 · see citing works
Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine
Apfelbaum, M., Vague, P., Ziegler, O., Hanotin, C., Thomas, F., & Leutenegger, É. (1999) · The American Journal of Medicine · doi:10.1016/s0002-9343(98)00411-2 · Cited by 343 · see citing works
Current and Potential Drugs for Treatment of Obesity
Bray, G. A., & Greenway, F. L. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.6.0383 · Cited by 326 · see citing works
Self-citation
Pharmacologic and Surgical Management of Obesity in Primary Care: A Clinical Practice Guideline from the American College of Physicians
Snow, V. T., Barry, P. P., Fitterman, N., Qaseem, A., & Weiss, K. B. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-7-200504050-00011 · Cited by 325 · see citing works
Clinical Efficacy of Orlistat Therapy in Overweight and Obese Patients With Insulin-Treated Type 2 Diabetes
Kelley, D. E., Bray, G. A., Pi-Sunyer, F. X., Klein, S., Hill, J., Miles, J., & Hollander, P. (2002) · Diabetes Care · doi:10.2337/diacare.25.6.1033 · Cited by 314 · see citing works
Self-citation
Exendin-4 Decelerates Food Intake, Weight Gain, and Fat Deposition in Zucker Rats
Szayna, M., Doyle, M. E., Betkey, J. A., Holloway, H. W., Spencer, R. G. S., Greig, N. H., & Egan, J. M. (2000) · Endocrinology · doi:10.1210/endo.141.6.7490 · Cited by 303 · see citing works
Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials
Haddock, C., Poston, W., Dill, P., Foreyt, J., & Ericsson, M. (2002) · International Journal of Obesity · doi:10.1038/sj.ijo.0801889 · Cited by 303 · see citing works
Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study.
Hill, J. O., Hauptman, J., Anderson, J. W., Fujioka, K., O'Neil, P. M., Smith, D. K., Zavoral, J. H., & Aronne, L. J. (1999) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/69.6.1108 · Cited by 287 · see citing works
Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin
Miles, J. M., Leiter, L., Hollander, P., Wadden, T., Anderson, J. W., Doyle, M., Foreyt, J., Aronne, L., & Klein, S. (2002) · Diabetes Care · doi:10.2337/diacare.25.7.1123 · Cited by 286 · see citing works
Long-term Weight Loss With Sibutramine
Wirth, A. G., & Krause, J. (2001) · JAMA · doi:10.1001/jama.286.11.1331 · Cited by 267 · see citing works
Cannabinoid receptors regulate Ca2+ signals and insulin secretion in pancreatic β-cell
Juan-Picó, P., Fuentes, E., Bermúdez-Silva, F., Díaz-Molina, F. J., Ripoll, C., de Fonseca, F. D., & Nadal, A. (2006) · Cell Calcium · doi:10.1016/j.ceca.2005.10.005 · Cited by 251 · see citing works
Efficacy and Safety of Sibutramine in Obese White and African American Patients With Hypertension
McMahon, F. G., Fujioka, K., Singh, B. N., Mendel, C. M., Rowe, E., Rolston, K., Johnson, F. K., & Mooradian, A. D. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.14.2185 · Cited by 246 · see citing works
Exenatide (Exendin-4) Improves Insulin Sensitivity and β-Cell Mass in Insulin-Resistant Obesefa/faZucker Rats Independent of Glycemia and Body Weight
Gedulin, B. R., Nikoulina, S. E., Smith, P. A., Gedulin, G., Nielsen, L. L., Baron, A., Parkes, D. G., & Young, A. A. (2004) · Endocrinology · doi:10.1210/en.2004-1349 · Cited by 241 · see citing works
Effectiveness of progressive dose‐escalation of exenatide (exendin‐4) in reducing dose‐limiting side effects in subjects with type 2 diabetes
Fineman, M. S., Shen, L. Z., Taylor, K., Kim, D. D. H., & Baron, A. (2004) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.499 · Cited by 227 · see citing works
Endocannabinoids in the regulation of appetite and body weight
Kirkham, T. C. (2005) · Behavioural Pharmacology · doi:10.1097/00008877-200509000-00004 · Cited by 220 · see citing works
Effects of Sibutramine Treatment in Obese Adolescents
Berkowitz, R. I., Fujioka, K., Daniels, S. R., Hoppin, A. G., Owen, S., PERRY, A. C., SOTHERN, M. S., Renz, C. L., PIRNER, M. A., Walch, J. K., et al. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-2-200607180-00005 · Cited by 219 · see citing works
Comparison of continuous and intermittent anorectic therapy in obesity.
Munro, J. F., MacCuish, A. C., Wilson, E. M., & Duncan, L. J. (1968) · BMJ · doi:10.1136/bmj.1.5588.352 · Cited by 215 · see citing works
What interventions should we add to weight reducing diets in adults with obesity? A systematic review of randomized controlled trials of adding drug therapy, exercise, behaviour therapy or combinations of these interventions
Avenell, A., Brown, T. J., McGee, M. A., Campbell, M., GRANT, A. M., Broom, J. I., Jung, R. T., & Smith, W. C. (2004) · Journal of Human Nutrition and Dietetics · doi:10.1111/j.1365-277x.2004.00530.x · Cited by 186 · see citing works
Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults
Erondu, N., Gantz, I., Musser, B. J., Suryawanshi, S., Mallick, M., Addy, C., Côté, J., Bray, G. A., Fujioka, K., Bays, H. E., et al. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.08.002 · Cited by 185 · see citing works
Self-citation
Thermogenic effects of sibutramine in humans
Hansen, D. L., Toubro, S., Stock, M. J., Macdonald, I. A., & Astrup, A. V. (1998) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/68.6.1180 · Cited by 182 · see citing works
Randomized, Double-Blind, Placebo-Controlled Trial of Orlistat for Weight Loss in Adolescents
Maahs, D. M., de Serna, D. G., Kolotkin, R. L., Ralston, S. L., Sandate, J., Qualls, C., & Schade, D. S. (2006) · Endocrine Practice · doi:10.4158/ep.12.1.18 · Cited by 177 · see citing works
Anorectics on Trial: A Half Century of Federal Regulation of Prescription Appetite Suppressants
Colman, E. G. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-143-5-200509060-00013 · Cited by 167 · see citing works
Effects of Obesity Surgery on Non–Insulin-Dependent Diabetes Mellitus
Greenway, S. E. (2002) · Archives of Surgery · doi:10.1001/archsurg.137.10.1109 · Cited by 166 · see citing works
A Systematic Review of Drug Therapy to Delay or Prevent Type 2 Diabetes
Padwal, R. S., Majumdar, S. R., Johnson, J. A., Varney, J., & McAlister, F. A. (2005) · Diabetes Care · doi:10.2337/diacare.28.3.736 · Cited by 164 · see citing works
Original Articles Sibutramine Reduces Food Intake in Non‐Dieting Women with Obesity
Rolls, B. J., Shide, D. J., Thorwart, M. L., & Ulbrecht, J. S. (1998) · Obesity Research · doi:10.1002/j.1550-8528.1998.tb00308.x · Cited by 158 · see citing works
Treatment of Obese Adolescents with Sibutramine: A Randomized, Double-Blind, Controlled Study
Godoy‐Matos, A. F., Carraro, L., Vieira, A., Oliveira, J., Guedes, E. P., Mattos, L., Rangel, C., Moreira, R. O., Coutinho, W. F., & Appolinário, J. C. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0263 · Cited by 158 · see citing works
Peripheral versus central effects of glucagon-like peptide-1 receptor agonists on satiety and body weight loss in Zucker obese rats
de Fonseca, F. R., Navarro, M. A., Álvarez, E., Roncero, I., Chowen, J. A., Maestre, O., de Heras, R. G., Muñoz, R. M., Eng, J., & Blázquez, E. (2000) · Metabolism · doi:10.1053/meta.2000.6251 · Cited by 157 · see citing works
Effect of anorexic drugs on food intake and the micro-structure of eating in human subjects
Rogers, P. J., & Blundell, J. E. (1979) · Psychopharmacology · doi:10.1007/bf00427624 · Cited by 148 · see citing works
Efficacy of Pharmacotherapy for Weight Loss in Adults With Type 2 Diabetes Mellitus
Norris, S. L., Zhang, X., Avenell, A., Gregg, E. W., Schmid, C. H., Kim, C., & Lau, J. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.13.1395 · Cited by 147 · see citing works
The Enteroinsular Axis and the Recovery from Type 2 Diabetes after Bariatric Surgery
Patriti, A., Facchiano, E., Sanna, A., Gullà, N., & Donini, A. (2004) · Obesity Surgery · doi:10.1381/0960892041590818 · Cited by 139 · see citing works
Glucagon-like Peptide 1 (GLP-1) Secretion and Plasma Dipeptidyl Peptidase IV (DPP-IV) Activity in Morbidly Obese Patients Undergoing Biliopancreatic Diversion
Lugari, R., Cas, A. D., Ugolotti, D., Barilli, A. L., Camellini, C., Ganzerla, G. C., Luciani, A., Salerni, B., Mittenperger, F., Nodari, S., et al. (2004) · Hormone and Metabolic Research · doi:10.1055/s-2004-814222 · Cited by 128 · see citing works
Effects of Sibutramine Plus Orlistat in Obese Women Following 1 Year of Treatment by Sibutramine Alone: A Placebo‐Controlled Trial
Wadden, T. A., Berkowitz, R. I., Womble, L. G., Sarwer, D. B., Arnold, M. E., & Steinberg, C. M. (2000) · Obesity Research · doi:10.1038/oby.2000.53 · Cited by 117 · see citing works
Orlistat Inhibits Dietary Cholesterol Absorption
Mittendorfer, B., Ostlund, R. E., Patterson, B. W., & Klein, S. (2001) · Obesity Research · doi:10.1038/oby.2001.79 · Cited by 114 · see citing works
Current and Potential Drugs for Treatment of Obesity
Bray, G. A. (1999) · Endocrine Reviews · doi:10.1210/er.20.6.805 · Cited by 111 · see citing works
Self-citation
Emerging Therapies Mimicking the Effects of Amylin and Glucagon-Like Peptide 1
Riddle, M. C., & Drucker, D. J. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1267 · Cited by 108 · see citing works
Effect of Sibutramine on Weight Loss and Blood Pressure: A Meta‐analysis of Controlled Trials
Kim, S. H., Lee, Y., Jee, S. H., & Nam, C. M. (2003) · Obesity Research · doi:10.1038/oby.2003.152 · Cited by 106 · see citing works
Effect of Sibutramine on Weight Management and Metabolic Control in Type 2 Diabetes
Vettor, R., Serra, R., Fabris, R., Pagano, C., & Federspil, G. (2005) · Diabetes Care · doi:10.2337/diacare.28.4.942 · Cited by 105 · see citing works
Eating behavior and adherence to dietary prescriptions in obese adult subjects treated with 5-hydroxytryptophan
Cangiano, C., Ceci, F., Cascino, A., Ben, M. D., Laviano, A., Muscaritoli, M., Antonucci, F., & Fanelli, F. R. (1992) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/56.5.863 · Cited by 102 · see citing works
A Typical Y1 Receptor Regulates Feeding Behaviors: Effects of a Potent and Selective Y1 Antagonist, J-115814
Kanatani, A., Hata, M., Mashiko, S., Ishihara, A., Okamoto, O., Haga, Y., Ohe, T., Kanno, T., Murai, N., Ishii, Y., et al. (2001) · Molecular Pharmacology · doi:10.1124/mol.59.3.501 · Cited by 99 · see citing works
Neuropeptide Y receptors as targets for anti-obesity drug development: perspective and current status
Parker, E. M., van Heek, M., & Stamford, A. W. (2002) · European Journal of Pharmacology · doi:10.1016/s0014-2999(02)01427-9 · Cited by 97 · see citing works
Influence of Sibutramine on blood pressure: evidence from placebo-controlled trials
Jordan, J., Scholze, J. E., Matiba, B., Wirth, A. G., Hauner, H., & Sharma, A. M. (2005) · International Journal of Obesity · doi:10.1038/sj.ijo.0802887 · Cited by 84 · see citing works
Long‐Term Systemic Exposure of Orlistat, a Lipase Inhibitor, and Its Metabolites in Obese Patients
Zhi, J., Mulligan, T. E., & Hauptman, J. B. (1999) · The Journal of Clinical Pharmacology · doi:10.1177/00912709922007543 · Cited by 83 · see citing works
5-Hydroxytryptamine 2C (5-HT2C) Receptor Agonists as Potential Antiobesity Agents
Nilsson, B. M. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm058240i · Cited by 75 · see citing works
Effects of oral 5-hydroxy-tryptophan on energy intake and macronutrient selection in non-insulin dependent diabetic patients
Cangiano, C., Laviano, A., Ben, M. D., Preziosa, I., Angelico, F., Cascino, A., & Fanelli, F. R. (1998) · International Journal of Obesity · doi:10.1038/sj.ijo.0800642 · Cited by 66 · see citing works
Long-term maintenance of weight loss with sibutramine in a GP setting following a specialist guided very-low-calorie diet: a double-blind, placebo-controlled, parallel group study
Mathus-Vliegen, E. M. H., & for the Balance Study Group (2005) · European Journal of Clinical Nutrition · doi:10.1038/sj.ejcn.1602172 · Cited by 59 · see citing works
Dihydropyridine Neuropeptide Y Y1 Receptor Antagonists
Poindexter, G. S., Bruce, M. A., LeBoulluec, K. L., Monković, I., Martin, S. W., Parker, E. M., Iben, L., McGovern, R. T., Ortiz, A. A., Stanley, J. A., et al. (2002) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(01)00761-2 · Cited by 54 · see citing works
Gut Hormones as Peripheral Anti Obesity Targets
Small, C. J., & Bloom, S. R. (2004) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1568007043336950 · Cited by 50 · see citing works
Sumatriptan decreases food intake and increases plasma growth hormone in healthy women
Boeles, S., Williams, C., Campling, G. M., Goodall, E. M., & Cowen, P. J. (1997) · Psychopharmacology · doi:10.1007/s002130050178 · Cited by 49 · see citing works
Orlistat: Selective Inhibition of Caloric Absorption Can Affect Long-Term Body Weight
Hauptman, J. B. (2000) · Endocrine · doi:10.1385/endo:13:2:201 · Cited by 38 · see citing works
Hypophagic, endocrine and subjective responses to m‐chlorophenylpiperazine in healthy men and women
Cowen, P. J., Sargent, P. A., Williams, C., Goodall, E. M., & Orlikov, A. B. (1995) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.470100504 · Cited by 36 · see citing works
Sibutramine and energy balance.
Astrup, A. V., Hansen, D. L., Lundsgaard, C. C., & Toubro, S. (1998) · PubMed · Cited by 36 · see citing works
Effect of fenfluramine on food intake, mood, and performance of humans living in a residential laboratory
Foltin, R. W., Haney, M., Comer, S. D., & Fischman, M. W. (1996) · Physiology & Behavior · doi:10.1016/0031-9384(95)02098-5 · Cited by 35 · see citing works
Neuropeptide Y Y5 receptor antagonists as anti-obesity drugs.
Levens, N. R., & Della‐Zuana, O. (2003) · PubMed · Cited by 28 · see citing works
The effect of dexfenfluramine on eating habits in a Dutch ambulatory android overweight population with an overconsumption of snacks.
Drent, M. L., ZELISSEN, P. M. J., Koppeschaar, H. P. F., Kruseman, A. C. N., Lutterman, J. A., & van der Veen, E. A. (1995) · PubMed · Cited by 20 · see citing works
Mutational analysis of the serotonin receptor 5HT2c in severe early-onset human obesity
Gibson, W. T., Ebersole, B. J., Bhattacharyya, S., Clayton, P., Farooqi, I. S., Sealfon, S. C., & O’Rahilly, S. (2004) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/y04-025 · Cited by 19 · see citing works
Neuropeptide Y in obese women during treatment with adrenergic modulation drugs.
Zahorska‐Markiewicz, B., Obuchowicz, E., Waluga, M., Tkacz, E., & Herman, Z. S. (2001) · PubMed · Cited by 18 · see citing works

Flagged first, then by citations

1 of the 90 references couldn’t be matched to a known paper.

Sorted by citations

Molecular and metabolic mechanisms of insulin resistance and β-cell failure in type 2 diabetes
Muoio, D. M., & Newgard, C. B. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2327 · Cited by 1,177 · see citing works
Obesity, Oxidative Stress, Adipose Tissue Dysfunction, and the Associated Health Risks: Causes and Therapeutic Strategies
Manna, P., & Jain, S. K. (2015) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2015.0095 · Cited by 1,167 · see citing works
Behavioral treatment of obesity
Butryn, M. L., Webb, V., & Wadden, T. A. (2011) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2011.08.006 · Cited by 636 · see citing works
Obesity‐Related Hypertension: Pathogenesis, Cardiovascular Risk, and Treatment: A Position Paper of The Obesity Society and the American Society of Hypertension
Landsberg, L., Aronne, L. J., Beilin, L. J., Burke, V., Igel, L. I., Lloyd‐Jones, D., & Sowers, J. (2013) · The Journal of Clinical Hypertension · doi:10.1111/jch.12049 · Cited by 528 · see citing works
Lifestyle modification for the management of obesity
Wadden, T. A., Butryn, M. L., & Wilson, C. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.051 · Cited by 406 · see citing works
Interfacial & colloidal aspects of lipid digestion
Wilde, P. J., & Chu, B. S. (2011) · Advances in Colloid and Interface Science · doi:10.1016/j.cis.2011.02.004 · Cited by 337 · see citing works
Natural Inhibitors of Pancreatic Lipase as New Players in Obesity Treatment
de la Garza, A. L., Milagro, F. I., Boqué, N., Campión, J., & Martínez, J. A. (2011) · Planta Medica · doi:10.1055/s-0030-1270924 · Cited by 285 · see citing works
Obesity‐related hypertension: Pathogenesis, cardiovascular risk, and treatment—A position paper of the The Obesity Society and the American Society of Hypertension
Landsberg, L., Aronne, L. J., Beilin, L. J., Burke, V., Igel, L. I., Lloyd‐Jones, D. M., & Sowers, J. R. (2012) · Obesity · doi:10.1002/oby.20181 · Cited by 286 · see citing works
Barriers to obesity treatment
Mauro, M., Taylor, V. H., Wharton, S., & Sharma, A. M. (2007) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2007.09.011 · Cited by 262 · see citing works
Prevalence, Pathophysiology, Health Consequences and Treatment Options of Obesity in the Elderly: A Guideline
Mathus-Vliegen, E. M. H., Basdevant, A., Finer, N., Hainer, V., Hauner, H., Micic, D., Maislos, M., Roman, G., Schutz, Y., Tsigos, C., et al. (2012) · Obesity Facts · doi:10.1159/000341193 · Cited by 261 · see citing works
Obesity and the Elderly
Mathus-Vliegen, E. M. H. (2012) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e31825692ce · Cited by 222 · see citing works
Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity
Supuran, C. T., Fiore, A. D., & Simone, G. D. (2008) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.13.2.383 · Cited by 216 · see citing works
Targeting obesity with plant-derived pancreatic lipase inhibitors: A comprehensive review
Logesh, R., Palaniswamy, D. S., & Mohankumar, S. K. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104681 · Cited by 197 · see citing works
Cardiovascular disease and modifiable cardiometabolic risk factors
Cannon, C. P. (2007) · Clinical cornerstone · doi:10.1016/s1098-3597(07)80025-1 · Cited by 175 · see citing works
Anti‐obesity action of gingerol: effect on lipid profile, insulin, leptin, amylase and lipase in male obese rats induced by a high‐fat diet
Saravanan, G., Ponmurugan, P., Deepa, M. A., & Senthilkumar, B. (2014) · Journal of the Science of Food and Agriculture · doi:10.1002/jsfa.6642 · Cited by 161 · see citing works
Drug-induced crystal nephropathy: an update
Yarlagadda, S. G., & Perazella, M. A. (2008) · Expert Opinion on Drug Safety · doi:10.1517/14740338.7.2.147 · Cited by 143 · see citing works
Behavioral and pharmacologic therapies for obesity
Vetter, M. L., Faulconbridge, L. F., Webb, V. L., & Wadden, T. A. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.121 · Cited by 124 · see citing works
New targets to treat obesity and the metabolic syndrome
Martin, K. A., Mani, M. V., & Mani, A. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.03.093 · Cited by 121 · see citing works
The efficiency of cellular energy transduction and its implications for obesity
Harper, M.-E., Green, K., & Brand, M. D. (2008) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.28.061807.155357 · Cited by 121 · see citing works
Role of the endocannabinoid system in drug addiction
Manzanares, J., Cabañero, D., Puente, N., García‐Gutiérrez, M. S., Grandes, P., & Maldonado, R. J. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.09.013 · Cited by 116 · see citing works
Reduced absorption of saturated fatty acids and resistance to diet-induced obesity and diabetes by ezetimibe-treated andNpc1l1−/−mice
Labonté, E. D., Camarota, L. M., Rojas, J. C., Jandacek, R. J., Gilham, D., Davies, J. P., Ioannou, Y. A., Tso, P., Hui, D. Y., & Howles, P. N. (2008) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.90275.2008 · Cited by 114 · see citing works
Lifestyle modification in the management of the metabolic syndrome: achievements and challenges
Marchesini, G. (2010) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmsott.s13860 · Cited by 108 · see citing works
Mechanisms responsible for excess weight loss after bariatric surgery
Ionut, V., & Bergman, R. N. (2011) · Journal of Diabetes Science and Technology · doi:10.1177/193229681100500536 · Cited by 105 · see citing works
Complementary and Alternative Medicine for the Treatment of Obesity: A Critical Review
Esteghamati, A., Mazaheri, T., Rad, M. V., & Noshad, S. (2015) · Intern J Endocrinol Metab · doi:10.5812/ijem.19678 · Cited by 99 · see citing works
Pharmacotherapeutic targeting of the endocannabinoid signaling system: Drugs for obesity and the metabolic syndrome
Vemuri, K. V., Janero, D. R., & Makriyannis, A. (2007) · Physiology & Behavior · doi:10.1016/j.physbeh.2007.11.012 · Cited by 100 · see citing works
Lifestyle modification in the management of the metabolic syndrome: achievements and challenges
Marchesini, G. (2010) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s13860 · Cited by 94 · see citing works
Cardiovascular Risk-Benefit Profile of Sibutramine
Scheen, A. J. (2010) · American Journal of Cardiovascular Drugs · doi:10.2165/11584800-000000000-00000 · Cited by 89 · see citing works
Pharmacologic Therapies for Obesity
Kaplan, L. M. (2010) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2010.01.001 · Cited by 74 · see citing works
Appetite Suppressants, Cardiac Valve Disease and Combination Pharmacotherapy
Rothman, R. B., & Baumann, M. H. (2008) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e31817fde95 · Cited by 64 · see citing works
The Pharmacological Treatment and Management of Obesity
Hussain, S. S., & Bloom, S. R. (2011) · Postgraduate Medicine · doi:10.3810/pgm.2011.01.2243 · Cited by 53 · see citing works
Weight-Gain in Psychiatric Treatment: Risks, Implications, and Strategies for Prevention and Management
Shrivastava, A., & Johnston, M. (2010) · Mens Sana monographs · doi:10.4103/0973-1229.58819 · Cited by 51 · see citing works
Role of Obesity in Cardiomyopathy and Pulmonary Hypertension
Cruz, C. S. D., & Matthay, R. A. (2009) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2009.06.001 · Cited by 49 · see citing works
Hypothalamic regulation of appetite
Simpson, K. A., Martin, N. M., & Bloom, S. R. (2008) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.3.5.577 · Cited by 49 · see citing works
The metabolic syndrome and cardiovascular disease: part 2.
Jiamsripong, P., Mookadam, M., Alharthi, M. S., Khandheria, B., & Mookadam, F. (2008) · Preventive Cardiology · doi:10.1111/j.1751-7141.2008.00002.x · Cited by 56 · see citing works
Obesity in Childhood and Adolescence, Genetic Factors
Kostovski, M., Tasic, V. B., Laban, N., Polenakovic, M. H., Danilovski, D., & Gucev, Z. S. (2017) · PRILOZI · doi:10.2478/prilozi-2018-0013 · Cited by 46 · see citing works
Spectrum of Drug-induced Chronic Diarrhea
Philip, N. A., Ahmed, N., & Pitchumoni, C. S. (2016) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000000752 · Cited by 42 · see citing works
The novel triple monoamine reuptake inhibitor tesofensine induces sustained weight loss and improves glycemic control in the diet-induced obese rat: Comparison to sibutramine and rimonabant
Hansen, H. H., Hansen, G., Tang‐Christensen, M., Larsen, P. J., Axel, A. M. D., Raben, A., & Mikkelsen, J. D. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2010.03.026 · Cited by 37 · see citing works
Effects of β‐aminoisobutyric acid on leptin production and lipid homeostasis: mechanisms and possible relevance for the prevention of obesity
Begriche, K., Massart, J., & Fromenty, B. (2009) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.2009.00765.x · Cited by 36 · see citing works
Cardiovascular Disease and Modifiable Cardiometabolic Risk Factors
Cannon, C. P. (2008) · Clinical cornerstone · doi:10.1016/s1098-3597(09)62037-8 · Cited by 33 · see citing works
Adult weight management: Translating research and guidelines into practice
Shay, L. E., Shobert, J. L., Seibert, D. C., & Thomas, L. E. (2009) · Journal of the American Academy of Nurse Practitioners · doi:10.1111/j.1745-7599.2008.00383.x · Cited by 32 · see citing works
Pharmacological Treatment of Obesity
Kabra, D. G., Kabra, U. D., Tschöp, M. H., & Hofmann, S. M. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3492-4_14 · Cited by 32 · see citing works
Current pharmacotherapeutic concepts for the treatment of obesity in adults
Idelevich, E. A., Kirch, W., & Schindler, C. (2008) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944708098226 · Cited by 29 · see citing works
Treatment of Obesity With “Combination” Pharmacotherapy
Rothman, R. B. (2010) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e31818e30da · Cited by 27 · see citing works
Nutrigenomic Analysis of Diet-Gene Interactions on Functional Supplements for Weight Management
Lau, F. C., Bagchi, M., Sen, C. K., Roy, S., & Bagchi, D. (2008) · Current Genomics · doi:10.2174/138920208784533638 · Cited by 26 · see citing works
Medications for Obesity: Mechanisms and Applications
Bray, G. A. (2009) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2009.05.014 · Cited by 25 · see citing works
Self-citation
Medications for Weight Reduction
Bray, G. A. (2008) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2008.08.004 · Cited by 24 · see citing works
Self-citation
Anti‐hypertensive treatment preserves appetite suppression while preventing cardiovascular adverse effects of tesofensine in rats
Bentzen, B. H., Grunnet, M., Hyveled‐Nielsen, L., Sundgreen, C., Lassen, J. B., & Hansen, H. H. (2013) · Obesity · doi:10.1002/oby.20122 · Cited by 22 · see citing works
Managing the combination of nonalcoholic fatty liver disease and metabolic syndrome
Moscatiello, S., Luzio, R. D., Sasdelli, A. S., & Marchesini, G. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.629188 · Cited by 20 · see citing works
Phentermine
Lim, S., Rogers, L. K., Tessler, O., Mundinger, G. S., Rogers, C. L., & Lau, F. H. (2018) · Annals of Plastic Surgery · doi:10.1097/sap.0000000000001478 · Cited by 20 · see citing works
A review on the molecular mechanisms, the therapeutic treatment including the potential of herbs and natural products, and target prediction of obesity-associated colorectal cancer
Yang, H., Yue, G. G., Leung, P. C., Wong, C. K., & Lau, C. B. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.106031 · Cited by 20 · see citing works
Advances in Medical Therapy for Weight Loss and the Weight-Centric Management of Type 2 Diabetes Mellitus
Igel, L. I., Powell, A. G., Apovian, C. M., & Aronne, L. J. (2011) · Current Atherosclerosis Reports · doi:10.1007/s11883-011-0221-0 · Cited by 20 · see citing works
Gastric electrical stimulation parameter dependently alters ventral medial hypothalamic activity and feeding in obese rats
Zhang, J., Maude‐Griffin, R., Zhu, H., Sun, Y., Starkebaum, W., Firestone, E. D., & Chen, J. D. Z. (2011) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00487.2010 · Cited by 20 · see citing works
OBESITY: DEVELOPMENT, EPIDEMIOLOGY, FACTORS AFFECTING, QUANTITY, HEALTH HAZARDS, MANAGEMENT AND NATURAL TREATMENT-A REVIEW
Bollapragada, M. K., Shantaram, M., & Sunil Kumar, R. (2017) · International Journal of Pharmacy and Pharmaceutical Sciences · doi:10.22159/ijpps.2017v9i2.15049 · Cited by 21 · see citing works
Efficacy and Tolerability of an Herbal Formulation for Weight Management
Stern, J. S., Peerson, J. M., Mishra, A., Mathukumalli, V. S. R., & Konda, P. R. (2013) · Journal of Medicinal Food · doi:10.1089/jmf.2012.0178 · Cited by 20 · see citing works
Chronic Disorders in Children and Adolescents
Goldstein, M. L., & Morewitz, S. J. (2011) · Springer eBooks · doi:10.1007/978-1-4419-9764-7 · Cited by 19 · see citing works
Long-term administration of an aqueous extract of dried, immature fruit of Poncirus trifoliata (L.) Raf. suppresses body weight gain in rats
Shim, W., Back, H., Seo, E. K., Lee, H.-T., & Shim, C. (2009) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2009.08.022 · Cited by 19 · see citing works
Key factors involved in obesity development
Wang, Z., Yuan, D., Duan, Y., Li, S., & Hou, S. (2017) · Eating and Weight Disorders - Studies on Anorexia Bulimia and Obesity · doi:10.1007/s40519-017-0428-3 · Cited by 19 · see citing works
Uso de drogas antiobesidade entre estudantes universitários
Martins, M. D. C. D. C. E., Filho, M. D. D. S., Moura, F. S., de Carvalho, J., Müller, M., Neves, R. V., Mousinho, P. C., & Lima, I. P. (2011) · Revista da Associação Médica Brasileira · doi:10.1590/s0104-42302011000500017 · Cited by 18 · see citing works
Therapeutic Role of Phytomedicines on Obesity: Importance of Herbal Pancreatic lipase Inhibitors
Singh, S., & Kanwar, S. S. (2013) · Cited by 18 · see citing works
Role of the endocannabinoid system in metabolic control
Wang, J., & Ueda, N. (2008) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0b013e3282f29071 · Cited by 17 · see citing works
Optimal locations and parameters of gastric electrical stimulation in altering ghrelin and oxytocin in the hypothalamus of rats
Zhang, J., Liu, S.-H., Tang, M., & Chen, J. D. Z. (2008) · Neuroscience Research · doi:10.1016/j.neures.2008.09.004 · Cited by 17 · see citing works
Treatment of Overweight and Obesity in Primary Care Practice: Current Evidence and Future Directions
Simkin‐Silverman, L. R., Conroy, M. B., & King, W. C. (2008) · American Journal of Lifestyle Medicine · doi:10.1177/1559827608317287 · Cited by 16 · see citing works
Small-Molecule Melanin-Concentrating Hormone-1 Receptor Antagonists Require Brain Penetration for Inhibition of Food Intake and Reduction in Body Weight
Hu, X., Wos, J. A., Dowty, M. E., Suchanek, P. M., Ji, W., Chambers, J. B., Benoit, S. C., Clegg, D. J., & Reizes, O. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.130435 · Cited by 15 · see citing works
Severe Symptomatic Hyponatremia During Sibutramine Therapy: A Case Report
Esposito, P. B., Rampino, T., Gregorini, M., Soccio, G., Piotti, G., Bedino, G., Balenzano, C. T., Roscini, E., Cosmai, L., Portalupi, V., et al. (2008) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2008.02.361 · Cited by 15 · see citing works
Obesity
Seagle, H. M., Wyatt, H. R., & Hill, J. O. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-391884-0.00024-x · Cited by 15 · see citing works
Use of anti-obesity drugs among college students
Martins, M. D. C. D. C. E., Filho, M. D. D. S., Moura, F. S., de Carvalho, J., Müller, M., Neves, R. V., Mousinho, P. C., & Lima, I. P. (2011) · Revista da Associação Médica Brasileira (English Edition) · doi:10.1016/s2255-4823(11)70113-8 · Cited by 13 · see citing works
Ischemic colitis after mesotherapy combined with anti-obesity medications
Kim, J. B. (2010) · World Journal of Gastroenterology · doi:10.3748/wjg.v16.i12.1537 · Cited by 13 · see citing works
Structure activity relationship studies of carboxamido-biaryl ethers as opioid receptor antagonists (OpRAs). Part 2
Takeuchi, K., Holloway, W. G., Mitch, C. H., Quimby, S. J., McKinzie, J. H., Suter, T. M., Statnick, M. A., Surface, P. L., Emmerson, P. J., Thomas, E. M., et al. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.10.025 · Cited by 13 · see citing works
Assessment of the Application of the Intragastric Balloon Together with Sibutramine: A Prospective Clinical Study
Coşkun, H., & Bostancı, Ö. (2008) · Obesity Surgery · doi:10.1007/s11695-008-9662-0 · Cited by 12 · see citing works
Lipase-Inhibitory and Anti-Oxidative Activity of the Methanol Extract and the Powder of Phellinus linteus
Kim, J., Son, I.-S., Kim, J., Kim, K., & Kwon, C.-S. (2008) · Journal of the Korean Society of Food Science and Nutrition · doi:10.3746/jkfn.2008.37.2.154 · Cited by 12 · see citing works
Piloting a New Approach to the Treatment of Obesity Using Dexamphetamine
Poulton, A. S., Hibbert, E., Champion, B. L., Cook, T. L., Alais, D., & Coulshed, D. S. (2015) · Frontiers in Endocrinology · doi:10.3389/fendo.2015.00014 · Cited by 12 · see citing works
Naringin ameliorates high-fat diet-induced hepatotoxicity and dyslipidemia in experimental rat model via modulation of anti-oxidant enzymes, AMPK and SERBP-1c signaling pathways
Sarkar, S., Ghosh, S., & Biswas, M. (2025) · Toxicology Reports · doi:10.1016/j.toxrep.2025.102062 · Cited by 11 · see citing works
Medications for Weight Reduction
Bray, G. A. (2011) · Medical Clinics of North America · doi:10.1016/j.mcna.2011.06.009 · Cited by 11 · see citing works
Self-citation
Effect of antiobesity medications in patients with type 2 diabetes mellitus
Choussein, S., Makri, A., Frangos, C. C., Petridou, E. T., & Daskalopoulou, S. S. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.01026.x · Cited by 11 · see citing works
Efficacy of chalcone and xanthine derivatives on lipase inhibition: A systematic review
Tam, D. N. H., Mostafa, E. M., Tu, V. L., Rashidy, A. I., Matenoglou, E., Kassem, M. A. M., Soa, D. T., Bayumi, A., Emam, H. E., Tran, L., et al. (2019) · Chemical Biology & Drug Design · doi:10.1111/cbdd.13626 · Cited by 10 · see citing works
Pilot study of temporary controllable gastric pseudobezoars for dynamic non-invasive gastric volume reduction
Mintchev, M. P., Deneva, M. G., Aminkov, B. I., Fattouche, M., Yadid-Pecht, O., & Bray, R. C. (2009) · Physiological Measurement · doi:10.1088/0967-3334/31/2/001 · Cited by 9 · see citing works
Combination treatment to CONQUER obesity?
Shah, K., & Villareal, D. T. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60518-7 · Cited by 9 · see citing works
Novel anti-obesity drugs and plasma lipids
Nikolić, D., Toth, P. P., Ferlita, A., Bartolo, V. D., Montalto, G., Banach, M., & Rizzo, M. (2014) · Clinical Lipidology · doi:10.2217/clp.14.7 · Cited by 8 · see citing works
Pharmacological Treatment of Obesity
Tek, C., Ratliff, J. C., & Chwastiak, L. (2011) · Psychiatric Annals · doi:10.3928/00485713-20110921-08 · Cited by 8 · see citing works
Metabolic improvement of morbid obese patients following Roux-en-Y gastric bypass surgery: A prospective study in Mashhad, Iran
Shahabad, S. F., Mazidi, M., Tavasoli, A., Rezaie, P., Rohani, F., Habibzadeh, S.-D., Darchini‐Maragheh, E., Sangsefidi‬, Z. S., Safarian, M., Ghayour‐Mobarhan, M., et al. (2016) · Indian Journal of Gastroenterology · doi:10.1007/s12664-016-0661-0 · Cited by 7 · see citing works
Food Intake and Body Weight Responses to Intermittent vs. Continuous Gastric Electrical Stimulation in Diet-Induced Obese Rats
Li, S., Maude‐Griffin, R., Sun, Y., Starkebaum, W., & Chen, J. D. Z. (2012) · Obesity Surgery · doi:10.1007/s11695-012-0773-2 · Cited by 7 · see citing works
Does innovation in obesity drugs affect stock markets? An event study analysis
Pérez–Rodríguez, J. V., & López‐Valcárcel, B. G. (2012) · Gaceta Sanitaria · doi:10.1016/j.gaceta.2011.07.028 · Cited by 7 · see citing works
DYSREGULATION OF THE AUTONOMIC NERVOUS SYSTEM IN THE MECHANISMS OF METABOLIC SYNDROME DEVELOPMENT
Ксенева, С. И., Бородулина, Е. В., Trifonova, O. Y., & Удут, В. В. (2019) · Сибирский журнал клинической и экспериментальной медицины · doi:10.29001/2073-8552-2018-33-4-119-124 · Cited by 6 · see citing works
Effect of Oleoylethanolamide-Based Dietary Supplement on Systemic Inflammation in the Development of Alimentary-Induced Obesity in Mice
Ivashkevich, D., Ponomarenko, A. I., Manzhulo, I., Sultanov, R. M., & Dyuizen, I. V. (2023) · Nutrients · doi:10.3390/nu15204345 · Cited by 8 · see citing works
Uso de medicamentos para perda de peso e índice de massa corporal em universitários do Vale do Araguaia (MT/GO), Amazônia Legal
de Toledo, O. R., de Castro, J. A. M., Honório‐França, A. C., França, E. L., & Ferrari, C. K. B. (2010) · Rev. Soc. Bras. Clín. Méd · Cited by 6 · see citing works
Effects of Ilex paraguariensis beverages on in vivo triglyceride and starch absorption in mice
Fioroto, C. K. S., da Silva, T. B. V., Castilho, P. A., Uber, T. M., de Sá‐Nakanishi, A. B., Seixas, F. A. V., Peralta, R. M., & Bracht, A. (2022) · Biocatalysis and Agricultural Biotechnology · doi:10.1016/j.bcab.2022.102330 · Cited by 6 · see citing works
Desipramine Inhibits Histamine H1 Receptor-Induced Ca2+ Signaling in Rat Hypothalamic Cells
Kang, J.-A., Lee, K., Lee, K. M., Cho, S., Seo, J., Hur, E., Park, C., Baik, J., & Choi, S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0036185 · Cited by 6 · see citing works
Therapeutics in Metabolic Diseases
Natesan, V. (2022) · Advances in experimental medicine and biology · doi:10.1007/978-981-19-5642-3_17 · Cited by 5 · see citing works
Tratamiento farmacológico o quirúrgico del paciente con sobrepeso u obesidad
Fernando Carrasco, N., Manrique, M., de la Maza, M. P., Moreno, M., Cecilia Albala, B., García, J., Díaz, J., & Liberman, C. (2009) · Revista médica de Chile · doi:10.4067/s0034-98872009000700017 · Cited by 5 · see citing works
The Relationship of Childhood Obesity with Cardiomyopathy and Heart Failure
Qureshi, M. Y., Wilkinson, J. D., & Lipshultz, S. E. (2012) · Springer eBooks · doi:10.1007/978-1-4471-2366-8_10 · Cited by 5 · see citing works
Drug Design of Antiobesity Carbonic Anhydrase Inhibitors
Simone, G. D., & Supuran, C. T. (2009) · doi:10.1002/9780470508169.ch10 · Cited by 5 · see citing works
Obtaining long-term recovery: advances in optimizing treatment outcomes in patients with binge-eating disorder
de Moraes, C. E. F., Donnelly, B., Appolinário, J. C., & Hay, P. (2023) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2023.2273392 · Cited by 3 · see citing works
Oral administration of Rehmannia glutinosa extract for obesity treatment via adiposity and fatty acid binding protein expression in obese rats
Park, M.-Y., Lee, H. J., Choi, D. H., Kang, B.-J., Choi, S., & Park, Y. S. (2017) · Toxicology and Environmental Health Sciences · doi:10.1007/s13530-017-0336-y · Cited by 3 · see citing works
Discoordination of Autonomic Support of Functions in the Pathogenesis Gastroesophageal Reflux Disease
Ксенева, С. И., Бородулина, Е. В., & Удут, В. В. (2018) · Bulletin of Experimental Biology and Medicine · doi:10.1007/s10517-018-4279-3 · Cited by 3 · see citing works
Use of anti-obesity drugs among college students
Martins, M. D. C. D. C. E., Filho, M. D. D. S., Moura, F. S., de Carvalho, J., Müller, M., Neves, R. V., Mousinho, P. C., & Lima, I. P. (2011) · Revista da Associação Médica Brasileira · doi:10.1016/s0104-4230(11)70113-0 · Cited by 3 · see citing works
Drugs Used Clinically to Reduce Body Weight
Bray, G. A. (2009) · Wiley eBooks · doi:10.1002/9781444307627.ch24 · Cited by 3 · see citing works
Self-citation
Drugs That Modify Fat Absorption and Alter Metabolism
Gaal, L. V. (2008) · CRC Press eBooks · doi:10.3109/9781420051452-20 · Cited by 2 · see citing works
Microbial metabolites beneficial in regulation of obesity
Khushboo, & Dubey, K. K. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-823506-5.00006-0 · Cited by 3 · see citing works
Changes in Appetite and Eating Behavior Associated with the Combination of Sibutramine and Behavior Therapy
Carvajal, R. (2011) · Digital Commons - PCOM (Philadelphia College of Osteopathic Medicine) · Cited by 1 · see citing works
Effect of oleoylethanolamide on systemic inflammation in the development of alimentary-induced obesity in micePreprint
Ivashkevich, D., Ponomarenko, A. I., Manzhulo, I., Sultanov, R. M., & Duizen, I. V. (2023) · Research Square · doi:10.21203/rs.3.rs-3094720/v1 · Cited by 1 · see citing works

State of the Art Review: Long-term Pharmacotherapy for Overweight and Obesity: A Review of Sibutramine, Orlistat, and Rimonabant
Dunican, K. C., Desilets, A. R., & DeBellis, R. J. (2007) · American Journal of Lifestyle Medicine · doi:10.1177/1559827607303256 · Cited by 3 · see citing works
Drug treatments for obesity
Couzigou, P. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60553-4 · Cited by 25 · see citing works
Pharmacological Management
Nisoli, E., & Muratori, F. (2015) · Springer eBooks · doi:10.1007/978-3-319-24532-4_5 · Cited by 1 · see citing works
[Drug treatment of obesity].
Svendsen, O. L., Toubro, S., Breum, L., Bruun, J. M., & Astrup, A. V. (2006) · PubMed · Cited by 1 · see citing works
Drug treatments for obesity: orlistat, sibutramine, and rimonabant
Padwal, R. S., & Majumdar, S. R. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60033-6 · Cited by 753 · see citing works

Authors: Bray, G. A., & Ryan, D. H.
Affiliations: Pennington Biomedical Research Center (US)
ORCID: Ryan, Donna H.
Venue: Gastroenterology
Publisher: Elsevier BV
Published: 2007-05
Volume: 132
Issue: 6
Pages: 2239-2252
ISSN: 0016-5085 (ISSN-L)
DOI: 10.1053/j.gastro.2007.03.053
OpenAlex: W2066499225
Cited by: 115
References: 90
Citations by year: 2026: 1 · 2025: 2 · 2023: 3 · 2022: 2 · 2021: 4 · 2020: 1 · 2019: 3 · 2018: 3 · 2017: 4 · 2016: 2 · 2015: 5 · 2014: 2 · 2013: 5 · 2012: 10
FWCI: 1.70
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Gastroenterology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Obesity, Physical Activity, Diet
Keywords: obesity, anti-obesity drugs, sibutramine, orlistat, rimonabant, weight maintenance, adverse drug reactions, elevated blood pressure, steatorrhea, gastrointestinal tolerance, long-term drug safety
MeSH terms: Rimonabant, Orlistat, Animals, Cyclobutanes, Humans, Lactones, Obesity, Piperidines, Pyrazoles, Treatment Outcome, Clinical Trials, Phase II as Topic, Anti-Obesity Agents, Overweight

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Drug Treatment of the Overweight Patient

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Cites

Cited by

Related

Record

About these checks